A detailed history of Centiva Capital, LP transactions in Incyte Corp stock. As of the latest transaction made, Centiva Capital, LP holds 6,253 shares of INCY stock, worth $435,396. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,253
Previous 9,583 34.75%
Holding current value
$435,396
Previous $580,000 28.79%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $190,908 - $228,471
-3,330 Reduced 34.75%
6,253 $413,000
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $187,267 - $233,261
3,659 Added 61.77%
9,583 $580,000
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $335,002 - $394,479
5,924 New
5,924 $337,000
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $59,454 - $74,437
-885 Reduced 26.1%
2,506 $201,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $23,361 - $29,249
353 Added 11.62%
3,391 $226,000
Q2 2022

Aug 17, 2022

SELL
$66.18 - $83.18 $191,922 - $241,222
-2,900 Reduced 48.84%
3,038 $231,000
Q2 2022

Aug 15, 2022

BUY
$66.18 - $83.18 $392,976 - $493,922
5,938 New
5,938 $453,000
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $239,058 - $288,629
-3,621 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $40,854 - $47,800
645 Added 21.67%
3,621 $266,000
Q3 2021

Nov 15, 2021

SELL
$68.67 - $84.02 $1.87 Million - $2.29 Million
-27,216 Reduced 90.14%
2,976 $205,000
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $1.52 Million - $1.66 Million
18,972 Added 169.09%
30,192 $2.54 Million
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $852,944 - $1.13 Million
11,220 New
11,220 $912,000
Q2 2020

Aug 14, 2020

SELL
$74.18 - $108.93 $911,375 - $1.34 Million
-12,286 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$63.18 - $85.97 $589,279 - $801,842
9,327 Added 315.21%
12,286 $899,000
Q4 2019

Feb 14, 2020

BUY
$73.04 - $95.72 $216,125 - $283,235
2,959 New
2,959 $258,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.